Method of treating neuroendocrine tumors
Methods and compositions for treating neuroendocrine tumors are disclosed.
1. A method of treating neuroendocrine tumor, comprising:
administering to a patient diagnosed with neuroendocrine tumor a therapeutically effective amount of a compound that is a pharmaceutically acceptable salt of trans-[tetrachlorobis(1H-indazole)ruthenate(III)].
2. The method of claim 1 , wherein said compound is an alkali metal salt of trans-[tetrachlorobis(1H-indazole)ruthenate(III)].
3. The method of claim 2 , wherein said compound is sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)].
4. The method of claim 3 , wherein the neuroendocrine tumor is carcinoid tumor.
5. The method of claim 4 , wherein the neuroendocrine tumor is carcinoid of the small intestine.
6. The method of claim 3 , wherein the neuroendocrine tumor is gastrinoma.
7. The method of claim 3 , wherein the neuroendocrine tumor is thyroid carcinoma or Merkel cell carcinoma.
8. The method of claim 3 , wherein the neuroendocrine tumor is a refractory neuroendocrine tumor previously treated with a regimen comprising one or more drugs selected from the group consisting of 5-FU, capecitabine, streptozocin, etoposide, doxorubicin, cisplatin, somatostatin analogs, and tyrosine kinase inhibitors.
9. A method of treating neuroendocrine tumor, comprising:
identifying a patient having neuroendocrine tumor; and treating the patient with a therapeutically effective amount of a compound that is a pharmaceutically acceptable salt of trans-[tetrachlorobis(1H-indazole)ruthenate(III)].